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Letters to the Editor76he VBT group. This group does not reflect the latest practice of
BT: the dose was lower, the patients in the study were treated
ith stents that were found to be associated with worse results
hen combined with VBT, and the duration of clopidogrel in that
ohort was limited. These issues raise flaws in the methodology
ecause the concurrent enrolled group and the historic group
hould not be pooled for the analysis.
Second, although the study was not powered to detect differ-
nces in hard clinical end points, at 3 years of follow-up, the overall
ardiac mortality, Q-wave and non–Q-wave MI were higher in the
ES group than in the VBT group. As detailed in Table 2 (1), the
verall mortality and incidence of MI increased with SES therapy
ver 38% and 48%, respectively.
Third, although the TLR was lower in the SES group, major
dverse cardiovascular events were similar, suggesting that the rise
n major adverse cardiovascular events with SES was related to an
ncrease of death and MI. In addition, the incidence of cumulative
tent thrombosis was higher in the SES-treated group (4.2%).
Fourth, Holmes et al. (1) suggested that there is clinical
vidence that coronary restenosis after BMS implantation is
ssociated with high incidence of MI and death (2). Currently,
ost BMS restenoses are treated with drug-eluting stents (DES),
hich are associated with high rate of late stent thrombosis and
erhaps lead to increase in death and MI (3).
In contrast, in the era before DES, BMS restenosis was not
ssociated with major incidence of death or MI. In the head-to-head
omparisons of BMS to coronary artery bypass graft, although BMS
as associated with increase of TLR when compared with coronary
rtery bypass graft, this was not associated with increase of mortality
r MI. In fact, in a recent meta-analysis from 4 large randomized
tudies (4), survival was almost identical in both BMS or coronary
rtery bypass graft groups in spite of repeat revascularization, which
as 4 times higher in BMS patients. In addition, in the ERACI III
Argentine Randomized Trial of Coronary Stents versus Bypass
urgery) study registry (5), at 3 years of follow-up, regardless to the
eduction of TLR, both DES and BMS groups had similar incidence
f death andMI, including diabetic patients. In ERACI III, all BMS
ata was collected in the era before DES; therefore, any BMS
estenoses had been treated with DES implantation.
In conclusion, the 3-year report of the SISR (Sirolimus-Eluting
tent Versus Vascular Brachytherapy for In-Stent Restenosis)
tudy alarms us regarding the high rates of stent thrombosis and
ortality and raises the question of what is the ideal therapy for
MS restenosis. Clearly when these patients are treated with SES,
hey should be monitored closely, perhaps with indefinite dual
ntiplatelet therapy, to prevent late events until we get more data
rom large randomized clinical trials and registries.
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eply
e thank Drs. Rodriguez and Waksman for the interest in our
tudy (1). Certainly, caution is always mandated as we evaluate
he longer-term outcome of strategies of care. Longer-term
ollow-up was very important for the field of vascular brachy-
herapy because it documented the late catch-up phenomenon
hat decreased the long-term effect of vascular brachytherapy
nd was one of the reasons vascular brachytherapy is rarely used
oday.
Drs. Rodriguez and Waksman reiterate our published comment
hat this “trial was neither powered nor designed for long-term
ollow-up” (1). It was powered for the primary 9-month end point.
lthough by protocol, patients continue to be followed up for 5 years.
Given the sample size of the population, the usual statistical
nalysis did not document a significant difference in cardiac
ortality. Obviously, longer-term follow-up to 5 years will be
mportant to see if trends emerge.
Drs. Rodriguez and Waksman are correct in that target
esion revascularization was indeed lower in the sirolimus-
luting stent group. There was a difference in absolute percent-
ge of stent thrombosis. We reported any Academic Research
onsortium (ARC) thrombosis as well as the other definitions
f thrombosis. Drs. Rodriguez and Waksman choose to focus
n any ARC thrombosis. However, most investigators prefer to
se definite or probable ARC thrombosis rates, which occurred
n 2.4% of vascular brachytherapy and 3.5% of sirolimus-eluting
tents (p  0.758).
Drs. Rodriguez and Waksman also support our belief that reste-
osis after bare-metal stents is not benign. This is not a new finding
nd we provided references (36) to (38) as further support (see
olmes et al. [1]).
Finally, we share the concerns of Drs. Rodriguez andWaksman.
n an era of bare-metal stent in-stent restenosis treated with
rug-eluting stents, our patients continue to need vigilant follow-
p. More data is certainly needed.
We do appreciate the concerns raised and believe they will only
e adequately addressed by larger numbers of patients with very
areful follow-up.
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